What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Prostate cancer, Surgery, Oncology and Docetaxel.
His research in Internal medicine intersects with topics in Gastroenterology and Endocrinology.
He has included themes like Hazard ratio and Urology in his Surgery study.
The study incorporates disciplines such as Bone metastasis and Prednisone in addition to Urology.
His Oncology research incorporates elements of Breast cancer, Clinical trial, Disease and Antigen.
His Docetaxel study combines topics in areas such as Febrile neutropenia, Cabazitaxel, Cancer biomarkers and Androgen receptor.
His most cited work include:
- Abiraterone and Increased Survival in Metastatic Prostate Cancer (3027 citations)
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy (2853 citations)
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy (1814 citations)
What are the main themes of his work throughout his whole career to date?
Karim Fizazi mainly focuses on Internal medicine, Oncology, Prostate cancer, Surgery and Docetaxel.
His work on Chemotherapy, Cancer, Hazard ratio and Clinical trial as part of general Internal medicine research is frequently linked to In patient, bridging the gap between disciplines.
The various areas that he examines in his Oncology study include Prostate-specific antigen, Clinical endpoint and Phases of clinical research.
His research on Prostate cancer often connects related topics like Prednisone.
His Surgery research integrates issues from Gastroenterology, Bone metastasis and Urology.
His Docetaxel research includes themes of Taxane, Cabazitaxel and Estramustine.
He most often published in these fields:
- Internal medicine (70.42%)
- Oncology (60.24%)
- Prostate cancer (59.02%)
What were the highlights of his more recent work (between 2018-2021)?
- Prostate cancer (59.02%)
- Internal medicine (70.42%)
- Oncology (60.24%)
In recent papers he was focusing on the following fields of study:
Karim Fizazi spends much of his time researching Prostate cancer, Internal medicine, Oncology, Castration resistant and In patient.
His biological study spans a wide range of topics, including Cancer research, Overall survival and Docetaxel.
His study in Internal medicine focuses on Darolutamide, Cancer, Clinical trial, Prednisone and Clinical endpoint.
His research integrates issues of Pembrolizumab and Abiraterone acetate in his study of Prednisone.
His study looks at the intersection of Oncology and topics like Androgen deprivation therapy with Urology.
His work is dedicated to discovering how Castration resistant, Olaparib are connected with Homologous recombination and other disciplines.
Between 2018 and 2021, his most popular works were:
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer (243 citations)
- Olaparib for metastatic castration-resistant prostate cancer (222 citations)
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. (153 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Karim Fizazi mostly deals with Prostate cancer, Internal medicine, Oncology, Castration resistant and Enzalutamide.
Karim Fizazi mostly deals with Androgen deprivation therapy in his studies of Prostate cancer.
His studies in Oncology integrate themes in fields like Radium-223, Meta-analysis, Docetaxel, Hazard ratio and Survival analysis.
His research investigates the connection between Castration resistant and topics such as Overall survival that intersect with issues in Hormone sensitive prostate cancer, Consensus conference, Androgen receptor and Safety profile.
He has researched Enzalutamide in several fields, including Olaparib and Cancer biomarkers.
His research investigates the connection with Progression-free survival and areas like Prednisone which intersect with concerns in Abiraterone acetate, Urology and Randomization.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
